GOVXHealthcare · BiotechnologyGOVX Stock Forecast: GeoVax Labs, Inc. Price Predictions for 2026-2027
The 2 Wall Street analysts covering GeoVax Labs, Inc. hold a median 12-month price target of $10 — +2289.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 14 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
GOVX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores GeoVax Labs, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (97): Smaller than most of the companies we track.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
GOVX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GOVX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +2289.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Apr 2026 | D. Boral Capital | Maintains | Hold | $1.00 |
| 19 Feb 2026 | D. Boral Capital | Downgrade | Hold | — |
| 21 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 19 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 26 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 7 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 29 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 17 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 2 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 28 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 31 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 Dec 2024 | D. Boral Capital | Maintains | Buy | — |
| 20 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Nov 2024 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GOVX appears on the weeks it earns a place.
GOVX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 15 Sept 2026, GeoVax Labs, Inc. returned −97.6% against +15.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
GOVX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
GeoVax Labs, Inc. (GOVX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.0×
- Price / sales
- 1.7×
- Price / book
- 1.9×
- EV / EBITDA
- −0.0×
Cheaper than 76% of US stocks
Cheaper than 57% of US stocks
Cheaper than 47% of US stocks
Cheaper than 61% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −862.3%
- Net margin
- 0.0%
Higher than 6% of US stocks
Higher than 30% of US stocks
- Return on equity
- −891.6%
- Return on assets
- −256.8%
- Dividend yield
- —
Higher than 2% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
GeoVax Labs, Inc. (GOVX) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
GeoVax Labs, Inc. has a market value of $4.2M and an enterprise value of $592K.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$20.4M.
Free cash flow in the twelve months to 30 June 2026: −$18.4M.
Trailing P/E: −0.0×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.
GeoVax Labs, Inc. employs 19 people.
Data provided by Twelve Data
GOVX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own GeoVax Labs, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about GOVX stock
What is the GOVX stock price forecast for 2026-2027?
The 2 Wall Street analysts covering GeoVax Labs, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is GOVX stock a buy right now?
Of the 2 analysts covering GeoVax Labs, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GeoVax Labs, Inc. 39 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GOVX?
As at 14 Sept 2026, GeoVax Labs, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).
Will GOVX stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +2289.5% from the last close, and Ticker Nerd's factor model ranks GeoVax Labs, Inc. 39 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the GOVX stock forecast for 2030?
No analyst covering GeoVax Labs, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GOVX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.
How has GOVX stock performed over the past year?
GeoVax Labs, Inc. returned -97.6% over the 12 months to 15 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
What does GeoVax Labs, Inc. do?
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and solid tumor cancers.
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and solid tumor cancers. GeoVax’s current portfolio centers on human vaccine candidates that address serious viral threats, including COVID-19, mpox, smallpox, and other high-consequence infectious diseases, alongside oncology programs aimed at difficult-to-treat solid tumors. The company’s pipeline includes vaccine and therapy development built on proprietary platform technologies designed to support immune responses across preventive and therapeutic settings. Its work spans infectious disease prevention, biodefense-related vaccines, and cancer immunotherapy, making GeoVax Labs a specialized player in the biotechnology market with an emphasis on unmet medical needs.
CEO Mr. David Alan Dodd · 19 employees · United States · https://www.geovax.com